About AKESO Company

Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs that are affordable to patients around the world. Since its establishment, the company has established an end-to-end comprehensive drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development, and production in line with GMP standards. The company has also successfully developed bispecific antibody drug development technology (Tetrabody technology), which can overcome the three CMC problems encountered in the development and production of bispecific antibodies, including 1. Inefficient expression levels, 2. Process development barriers, and 3. Antibody stability and pharmacogenicity. Up to now, the company has more than 50 research and innovation projects, covering various fields such as oncology, autoimmune and metabolic diseases. Among them, 71 self-developed products have been approved for marketing and 1 product is under NMPA marketing review. A total of 12 products are undergoing registered phase III clinical trials, and 12 products are in phase I/II clinical trials. Of the pipeline products, 15 are potentially the world's first (first-in-class) or best-in-class (best-in-class) dual-anti/multi-antibody ADCs. The company's vision is to become the world's leading biopharmaceutical company by focusing on R&D and innovation, establishing a world-class production system, and continuously expanding its business network.